Literature DB >> 17525730

Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

M Jiménez1, G Ercilla, C Martínez.   

Abstract

Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SCT are associated with high rates of non-relapse mortality. One of the theoretical advantages of RIC-SCT is that it might lend to better immune reconstitution after transplantation due to less damage of the thymus, allowing regeneration of naive T cells derived from prethymic donor stem cells, and due to the proliferation of immunologically competent host T cells that survive the conditioning regimen. Although limited, studies comparing immune recovery following RIC and MAC-SCT have been insightful. One of the main difficulties of these studies is the current spectrum of RIC protocols, which vary considerably in myeloablative and immunosuppressive potential, resulting in apparently contradictory findings. In spite of this, most reports have shown significant quantitative and/or qualitative differences in T- and B-cell reconstitution after RIC-SCT in comparison with conventional SCT. This paper will review current knowledge of immune reconstitution following RIC-SCT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525730     DOI: 10.1038/sj.leu.2404681

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

Review 2.  Thymic T-cell development in allogeneic stem cell transplantation.

Authors:  Werner Krenger; Bruce R Blazar; Georg A Holländer
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

3.  Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.

Authors:  Raphael Itzykson; Marie Robin; Helene Moins-Teisserenc; Marc Delord; Marc Busson; Aliénor Xhaard; Flore Sicre de Fontebrune; Régis Peffault de Latour; Antoine Toubert; Gérard Socié
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

4.  Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies.

Authors:  Michael J Burke; Rachel Isaksson Vogel; Sanyukta K Janardan; Claudio Brunstein; Angela R Smith; Jeffrey S Miller; Daniel Weisdorf; John E Wagner; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-08       Impact factor: 5.742

5.  Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.

Authors:  Kyle Peake; John Manning; Coral-Ann Lewis; Christine Barr; Fabio Rossi; Charles Krieger
Journal:  J Vis Exp       Date:  2015-04-01       Impact factor: 1.355

6.  Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion.

Authors:  Martin Schmidt-Hieber; S Schwarck; A Stroux; S Ganepola; P Reinke; E Thiel; L Uharek; I W Blau
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

7.  Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation.

Authors:  Shivtia Trop-Steinberg; Yehudith Azar; Rachel Bringer; Reuven Or
Journal:  Clin Exp Med       Date:  2014-08-07       Impact factor: 3.984

Review 8.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

9.  Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies.

Authors:  Elisabeth Ersvaer; Kimberley J Hatfield; Håkon Reikvam; Oystein Bruserud
Journal:  Bone Marrow Res       Date:  2010-10-04

10.  Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.

Authors:  Li Xuan; Fen Huang; Zhiping Fan; Hongsheng Zhou; Xian Zhang; Guopan Yu; Yu Zhang; Can Liu; Jing Sun; Qifa Liu
Journal:  J Hematol Oncol       Date:  2012-08-02       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.